22nd Century Group to Open Laboratories to Lower Costs of Research and Speed Development of Important New Products
November 24 2015 - 1:12PM
Business Wire
Company to Present at LD Micro Investor
Conference on December 2nd
22nd Century Group, Inc. (NYSE MKT: XXII), a plant
biotechnology company that is a leader in tobacco harm reduction,
announced today that it will open specialized laboratories in
Western New York dedicated to new scientific research at
substantially lower costs than sponsored research projects at
third-party universities. Paul J. Rushton, Ph.D., the Company’s
recently appointed Cambridge and Max Planck Institute-educated Vice
President of Plant Biotechnology, will lead this new scientific
initiative. The new laboratories will accelerate the development of
new nicotine-free tobacco varieties as well as the invention of
important tobacco products.
Dr. Rushton explained, “This is a very exciting time for our
Company. Our new laboratories will provide 22nd Century with the
in-house capabilities to rapidly expand our genomics-based research
and to accelerate commercialization of our technologies.”
“The new 22nd Century laboratories will enable us to continue to
grow our patent portfolio – but at substantially reduced costs,”
explained Henry Sicignano III, President and CEO of 22nd Century
Group. “What’s more, using our own labs will enable us to own,
outright, the patents that we develop rather than having to license
them from sponsored third-party researchers.”
In other news, 22nd Century announced today that the Company
will present at the LD Micro Invitational Conference at the Luxe
Sunset Boulevard Hotel, 11461 Sunset Boulevard, Los Angeles,
California, on Wednesday, December 2, 2015 at 1:30 p.m. PST.
The LD Micro investor conference focuses on revealing to
qualified investors promising, undervalued companies in the
micro-cap space. Mr. Sicignano will provide attendees with a formal
update, business overview, and highlights of recent 22nd Century
Group activity. In addition, Mr. Sicignano will be available for
one-on-one meetings at the conference.
To arrange a one-on-one meeting with 22nd Century, please
contact Andrew Haag at xxii@irthcommunications.com or call
866-976-4784.
About 22nd Century Group, Inc.
22nd Century Group is a plant biotechnology company focused on
technology which allows it to increase or decrease the level of
nicotine in tobacco plants and the level of cannabinoids in
cannabis plants through genetic engineering and plant breeding. The
Company’s primary mission is to reduce the harm caused by smoking.
22nd Century currently owns or exclusively controls more than 200
issued patents and more than 50 pending patent applications around
the world. The Company’s strong IP position led to a licensing
agreement with British American Tobacco (“BAT”), the world’s second
largest tobacco company. Visit www.xxiicentury.com for more
information.
Cautionary Note Regarding Forward-Looking Statements: This press
release contains forward-looking information, including all
statements that are not statements of historical fact regarding the
intent, belief or current expectations of 22nd Century Group, Inc.,
its directors or its officers with respect to the contents of this
press release, including but not limited to our future revenue
expectations. The words “may,” “would,” “will,” “expect,”
“estimate,” “anticipate,” “believe,” “intend” and similar
expressions and variations thereof are intended to identify
forward-looking statements. We cannot guarantee future results,
levels of activity or performance. You should not place undue
reliance on these forward-looking statements, which speak only as
of the date that they were made. These cautionary statements should
be considered with any written or oral forward-looking statements
that we may issue in the future. Except as required by applicable
law, including the securities laws of the United States, we do not
intend to update any of the forward-looking statements to conform
these statements to reflect actual results, later events or
circumstances, or to reflect the occurrence of unanticipated
events. You should carefully review and consider the various
disclosures made by us in our annual report on Form 10-K for the
fiscal year ended December 31, 2014, filed on February 5, 2015,
including the section entitled “Risk Factors,” and our other
reports filed with the U.S. Securities and Exchange Commission
which attempt to advise interested parties of the risks and factors
that may affect our business, financial condition, results of
operation and cash flows. If one or more of these risks or
uncertainties materialize, or if the underlying assumptions prove
incorrect, our actual results may vary materially from those
expected or projected.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151124006043/en/
Investor Relations:IRTH CommunicationsAndrew Haag,
866-976-4784xxii@irthcommunications.comorRedington, Inc.Tom
Redington, 203-222-7399
22nd Century (AMEX:XXII)
Historical Stock Chart
From Aug 2024 to Sep 2024
22nd Century (AMEX:XXII)
Historical Stock Chart
From Sep 2023 to Sep 2024